The era of antiretroviral therapy has made HIV-1 infection a manageable chronic disease for
those with access to treatment. Despite treatment, virus persists in tissue reservoirs seeded …

Future HIV-1 curative therapies require a thorough understanding of the distribution of
genetically-intact HIV-1 within T-cell subsets during antiretroviral therapy (ART) and the …

HIV-1–infected individuals harbor a latent reservoir of infected CD4+ T cells that is not
eradicated by antiretroviral therapy (ART). This reservoir presents the greatest barrier to an …

Despite antiretroviral therapy, HIV-1 persists in memory CD4+ T cells, creating a barrier to
cure. The majority of HIV-1 proviruses are defective and considered clinically irrelevant …

Background The latent human immunodeficiency virus type 1 (HIV-1) reservoir represents a
major barrier to a cure. Based on the levels of HIV-1 DNA in naive (TN) vs resting memory …

Abstract Memory CD4+ T cells (mCD4s) containing integrated HIV DNA are considered the
main barrier to a cure for HIV infection. Here, we analyzed HIV DNA reservoirs in antigen …

Background Molecular latency allows HIV-1 to persist in resting memory CD4+ T-cells as
transcriptionally silent provirus integrated into host chromosomal DNA. Multiple …

Antiretroviral therapy controls HIV replication but does not eliminate the virus from the
infected host. The persistence of a small pool of cells harboring integrated and replication …

The introduction of antiretroviral therapy (ART) 20 years ago has dramatically reduced
morbidity and mortality associated with HIV-1. Initially there was hope that ART would be …

The introduction of highly active antiretroviral therapy (HAART) has been an important
breakthrough in the treatment of HIV‐1 infection and has also a powerful tool to upset the …